ID

12973

Descrizione

Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT02177422

collegamento

https://clinicaltrials.gov/show/NCT02177422

Keywords

  1. 08/01/16 08/01/16 -
Titolare del copyright

CC BY-NC 3.0

Caricato su

8 gennaio 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Hypertension NCT02177422

Eligibility Hypertension NCT02177422

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. all patients must give a separate written informed consent for participation in the open-label follow-up.
Descrizione

patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. all patients must give a separate written informed consent for participation in the open-label follow-up.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2]
C0248719
mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of ≥ 95 mmhg measured by manual cuff sphygmomanometer
Descrizione

hypertension

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0020538
mean seated systolic blood pressure ≥ 140 mmhg, measured my manual cuff
Descrizione

mean seated systolic blood pressure ≥ 140 mmhg, measured my manual cuff

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005823
a 24-hour mean diastolic blood pressure, measured by abpm (ambulatory blood pressure measurement), of ≥ 85 mmhg
Descrizione

a 24-hour mean diastolic blood pressure, measured by abpm (ambulatory blood pressure measurement), of ≥ 85 mmhg

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005823
age 18 or older
Descrizione

age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
patient's written informed consent in accordance with gcp (good clinical practice) and local legislation
Descrizione

informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with a clinically significant change in ecg from baseline that was reported as an adverse event during the preceding clinical trial
Descrizione

patients with a clinically significant change in ecg from baseline that was reported as an adverse event during the preceding clinical trial

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1623258
patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan
Descrizione

patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2348563
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
patients who discontinued the preceding telmisartan clinical trial due to an adverse event
Descrizione

patients who discontinued the preceding telmisartan clinical trial due to an adverse event

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan
Descrizione

any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2348563
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488

Similar models

Eligibility Hypertension NCT02177422

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. all patients must give a separate written informed consent for participation in the open-label follow-up.
Item
patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. all patients must give a separate written informed consent for participation in the open-label follow-up.
boolean
C0021430 (UMLS CUI [1])
C0248719 (UMLS CUI [2])
hypertension
Item
mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of ≥ 95 mmhg measured by manual cuff sphygmomanometer
boolean
C0020538 (UMLS CUI [1])
mean seated systolic blood pressure ≥ 140 mmhg, measured my manual cuff
Item
mean seated systolic blood pressure ≥ 140 mmhg, measured my manual cuff
boolean
C0005823 (UMLS CUI [1])
a 24-hour mean diastolic blood pressure, measured by abpm (ambulatory blood pressure measurement), of ≥ 85 mmhg
Item
a 24-hour mean diastolic blood pressure, measured by abpm (ambulatory blood pressure measurement), of ≥ 85 mmhg
boolean
C0005823 (UMLS CUI [1])
age
Item
age 18 or older
boolean
C0001779 (UMLS CUI [1])
informed consent
Item
patient's written informed consent in accordance with gcp (good clinical practice) and local legislation
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
patients with a clinically significant change in ecg from baseline that was reported as an adverse event during the preceding clinical trial
Item
patients with a clinically significant change in ecg from baseline that was reported as an adverse event during the preceding clinical trial
boolean
C1623258 (UMLS CUI [1])
patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan
Item
patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
patients who discontinued the preceding telmisartan clinical trial due to an adverse event
Item
patients who discontinued the preceding telmisartan clinical trial due to an adverse event
boolean
C2348568 (UMLS CUI [1])
any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan
Item
any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial